|
1
|
Bray F, Ren JS, Masuyer E and Ferlay J:
Global estimates of cancer prevalence for 27 sites in the adult
population in 2008. Int J Cancer. 132:1133–1145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Garcia-Closas M, Hall P, Nevanlinna H,
Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG,
Axelsson CK, Arias JI, et al: Heterogeneity of breast cancer
associations with five susceptibility loci by clinical and
pathological characteristics. PLoS Genet. 4:e10000542008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gianni L, Dafni U, Gelber RD, Azambuja E,
Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch
C, et al: Treatment with trastuzumab for 1 year after adjuvant
chemotherapy in patients with HER2-positive early breast cancer: A
4-year follow-up of a randomised controlled trial. Lancet Oncol.
12:236–244. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hu DG, Selth LA, Tarulli GA, Meech R,
Wijayakumara D, Chanawong A, Russell R, Caldas C, Robinson JL,
Carroll JS, et al: Androgen and estrogen receptors in breast cancer
coregulate human UDP-glucuronosyltransferases 2B15 and 2B17. Cancer
Res. 76:5881–5893. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weigel MT and Dowsett M: Current and
emerging biomarkers in breast cancer: Prognosis and prediction.
Endocr Relat Cancer. 17:R245–R262. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cancer Genome Atlas Network, .
Comprehensive molecular portraits of human breast tumours. Nature.
490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zeng H, Zheng R, Zhang S, Zou X and Chen
W: Female breast cancer statistics of 2010 in China: Estimates
based on data from 145 population-based cancer registries. J Thorac
Dis. 6:466–470. 2014.PubMed/NCBI
|
|
8
|
Becker MA, Ibrahim YH, Cui X, Lee AV and
Yee D: The IGF pathway regulates ERα through a S6K1-dependent
mechanism in breast cancer cells. Mol Endocrinol. 25:516–528. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sarfstein R, Pasmanik-Chor M, Yeheskel A,
Edry L, Shomron N, Warman N, Wertheimer E, Maor S, Shochat L and
Werner H: Insulin-like growth factor-I receptor (IGF-IR)
translocates to nucleus and autoregulates IGF-IR gene expression in
breast cancer cells. J Biol Chem. 287:2766–2776. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Giovannucci E: Insulin-like growth
factor-I and binding protein-3 and risk of cancer. Horm Res. 51
Suppl 3:S34–S41. 1999.
|
|
11
|
Gong Y, Yao E, Shen R, Goel A, Arcila M,
Teruya-Feldstein J, Zakowski MF, Frankel S, Peifer M, Thomas RK, et
al: High expression levels of total IGF-1R and sensitivity of NSCLC
cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One.
4:e72732009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kucab JE and Dunn SE: Role of IGF-1R in
mediating breast cancer invasion and metastasis. Breast Dis.
17:41–47. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Valsecchi ME, McDonald M, Brody JR, Hyslop
T, Freydin B, Yeo CJ, Solomides C, Peiper SC and Witkiewicz AK:
Epidermal growth factor receptor and insulinlike growth factor 1
receptor expression predict poor survival in pancreatic ductal
adenocarcinoma. Cancer. 118:3484–3493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Farabaugh SM, Boone DN and Lee AV: Role of
IGF1R in breast cancer subtypes, stemness, and lineage
differentiation. Front Endocrinol (Lausanne). 6:592015.PubMed/NCBI
|
|
15
|
Christopoulos PF, Msaouel P and
Koutsilieris M: The role of the insulin-like growth factor-1 system
in breast cancer. Mol Cancer. 14:432015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Papa V, Gliozzo B, Clark GM, McGuire WL,
Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID and Pezzino V:
Insulin-like growth factor-I receptors are overexpressed and
predict a low risk in human breast cancer. Cancer Res.
53:3736–3740. 1993.PubMed/NCBI
|
|
17
|
Bahhnassy A, Mohanad M, Shaarawy S, Ismail
MF, El-Bastawisy A, Ashmawy AM and Zekri AR: Transforming growth
factor-β, insulin-like growth factor I/insulin-like growth factor I
receptor and vascular endothelial growth factor-A: Prognostic and
predictive markers in triple-negative and non-triple-negative
breast cancer. Mol Med Rep. 12:851–864. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kelly GM, Buckley DA, Kiely PA, Adams DR
and O'Connor R: Serine phosphorylation of the insulin-like growth
factor I (IGF-1) receptor C-terminal tail restrains kinase activity
and cell growth. J Biol Chem. 287:28180–28194. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gradishar WJ, Anderson BO, Balassanian R,
Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A,
Giordano SH, et al: Breast cancer version 2.2015. J Natl Compr Canc
Netw. 13:448–475. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hartog H, Horlings HM, van der Vegt B,
Kreike B, Ajouaou A, van de Vijver MJ, Marike Boezen H, de Bock GH,
van der Graaf WT and Wesseling J: Divergent effects of insulin-like
growth factor-1 receptor expression on prognosis of estrogen
receptor positive versus triple negative invasive ductal breast
carcinoma. Breast Cancer Res Treat. 129:725–736. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yerushalmi R, Gelmon KA, Leung S, Gao D,
Cheang M, Pollak M, Turashvili G, Gilks BC and Kennecke H:
Insulin-like growth factor receptor (IGF-1R) in breast cancer
subtypes. Breast Cancer Res Treat. 132:131–142. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI
|
|
23
|
Friedrichs K, Gluba S, Eidtmann H and
Jonat W: Overexpression of p53 and prognosis in breast cancer.
Cancer. 72:3641–3647. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao S, Chen SS, Gu Y, Jiang EZ and Yu ZH:
Expression and clinical significance of sushi domain-containing
protein 3 (SUSD3) and insulin-like growth factor-I receptor
(IGF-IR) in breast cancer. Asian Pac J Cancer Prev. 16:8633–8636.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Heskamp S, Boerman OC, Molkenboer-Kuenen
JD, Wauters CA, Strobbe LJ, Mandigers CM, Bult P, Oyen WJ, van der
Graaf WT and van Laarhoven HW: Upregulation of IGF-1R expression
during neoadjuvant therapy predicts poor outcome in breast cancer
patients. PLoS One. 10:e01177452015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mauro L, Naimo GD, Ricchio E, Panno ML and
Andò S: Cross-Talk between adiponectin and IGF-IR in breast cancer.
Front Oncol. 5:1572015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Surmacz E: Growth factor receptors as
therapeutic targets: Strategies to inhibit the insulin-like growth
factor I receptor. Oncogene. 22:6589–6597. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Su B, Wong C, Hong Y and Chen S: Growth
factor signaling enhances aromatase activity of breast cancer cells
via post-transcriptional mechanisms. J Steroid Biochem Mol Biol.
123:101–108. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Casa AJ, Potter AS, Malik S, Lazard Z,
Kuiatse I, Kim HT, Tsimelzon A, Creighton CJ, Hilsenbeck SG, Brown
PH, et al: Estrogen and insulin-like growth factor-I (IGF-I)
independently down-regulate critical repressors of breast cancer
growth. Breast Cancer Res Treat. 132:61–73. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Corcoran C, Rani S, Breslin S, Gogarty M,
Ghobrial IM, Crown J and O'Driscoll L: miR-630 targets IGF1R to
regulate response to HER-targeting drugs and overall cancer cell
progression in HER2 over-expressing breast cancer. Mol Cancer.
13:712014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ye XM, Zhu HY, Bai WD, Wang T, Wang L,
Chen Y, Yang AG and Jia LT: Epigenetic silencing of miR-375 induces
trastuzumab resistance in HER2-positive breast cancer by targeting
IGF1R. BMC Cancer. 14:1342014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vogel CL, Cobleigh MA, Tripathy D, Gutheil
JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF,
Burchmore M, et al: Efficacy and safety of trastuzumab as a single
agent in first-line treatment of HER2-overexpressing metastatic
breast cancer. J Clin Oncol. 20:719–726. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nahta R, Yuan LX, Zhang B, Kobayashi R and
Esteva FJ: Insulin-like growth factor-I receptor/human epidermal
growth factor receptor 2 heterodimerization contributes to
trastuzumab resistance of breast cancer cells. Cancer Res.
65:11118–11128. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen C, Zhang Y, Zhang Y, Li J, Tsao SW
and Zhang MY: Superior antitumor activity of a novel bispecific
antibody cotargeting human epidermal growth factor receptor 2 and
type I insulin-like growth factor receptor. Mol Cancer Ther.
13:90–100. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Papa A, Caruso D, Tomao S, Rossi L,
Zaccarelli E and Tomao F: Triple-negative breast cancer:
Investigating potential molecular therapeutic target. Expert Opin
Ther Targets. 19:55–75. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mancini P, Angeloni A, Risi E, Orsi E and
Mezi S: Standard of care and promising new agents for triple
negative metastatic breast cancer. Cancers (Basel). 6:2187–2223.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Masuda H, Baggerly KA, Wang Y, Zhang Y,
Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD,
Pietenpol JA, Hortobagyi GN, et al: Differential response to
neoadjuvant chemotherapy among 7 triple-negative breast cancer
molecular subtypes. Clin Cancer Res. 19:5533–5540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shimizu C, Hasegawa T, Tani Y, Takahashi
F, Takeuchi M, Watanabe T, Ando M, Katsumata N and Fujiwara Y:
Expression of insulin-like growth factor 1 receptor in primary
breast cancer: Immunohistochemical analysis. Hum Pathol.
35:1537–1542. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Law JH, Habibi G, Hu K, Masoudi H, Wang
MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, et al:
Phosphorylated insulin-like growth factor-i/insulin receptor is
present in all breast cancer subtypes and is related to poor
survival. Cancer Res. 68:10238–10246. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Haffty BG, Yang Q, Reiss M, Kearney T,
Higgins SA, Weidhaas J, Harris L, Hait W and Toppmeyer D:
Locoregional relapse and distant metastasis in conservatively
managed triple negative early-stage breast cancer. J Clin Oncol.
24:5652–5657. 2006. View Article : Google Scholar : PubMed/NCBI
|
